Titan Medical Inc.
TMDI · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | -0.07 | 0.01 | -0.01 |
| FCF Yield | -16.80% | -17.39% | -3.57% | -17.92% |
| EV / EBITDA | -3.97 | -3.55 | -3.28 | 3.96 |
| Quality | ||||
| ROIC | -121.63% | -61.48% | -32.91% | 25.56% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.79 | 0.88 | 0.21 | -1.30 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.00% | -0.00% | 2,716,261.56% | 2,718,518.46% |
| Free Cash Flow Growth | 14.11% | -369.61% | 83.19% | -18.11% |
| Safety | ||||
| Net Debt / EBITDA | 1.00 | 1.75 | 3.19 | -3.18 |
| Interest Coverage | -245.90 | -639.18 | -511.28 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 74.52 |